Pds Biotechnology Corp

This management proposal requests shareholder approval to amend the Company’s Eighth Amended and Restated Certificate of Incorporation to double the authorized shares of common stock from 150 million to 300 million. Management and the Board frame the request as a measure to ensure sufficient authorized but unissued shares to support future capital raises, equity compensation programs, strategic transactions, acquisitions, stock splits or other corporate needs without requiring repeated shareholder approvals that could delay actions. As of the record date the company had approximately 55.8 million shares outstanding and roughly 2.13 million shares reserved under equity plans, leaving a limited buffer of available authorized shares; management indicates no current commitments to issue the additional shares. The Board unanimously recommends approval, arguing that the expanded authorization provides flexibility to execute financing or strategic initiatives quickly and to grant stock-based incentives to employees and partners. The filing flags potential dilution and notes that additional issuances could dilute existing holders’ ownership and voting power and could, under certain circumstances, have anti-takeover effects; the Board presents these as potential consequences rather than intended effects. The amendment would not change existing shareholder rights, does not grant preemptive rights, and would become effective upon filing the Certificate of Amendment with the Delaware Secretary of State. From a governance perspective, approval gives management unilateral authority (subject to legal and exchange rules) to issue more shares, which can be pro-management in financing or defense contexts and could depress per-share metrics if used aggressively. Investors should weigh the company’s near-term financing needs and capital plan, as well as historical dilution patterns and management’s disclosure about intended uses, when assessing the merits of this authorization increase.

This management-sponsored non-binding proposal asks shareholders to approve the Company’s disclosed executive compensation for named executive officers. Management frames the vote as a broad endorsement of the compensation philosophy, which emphasizes incentives linked to R&D milestones, clinical progress, regulatory achievements, strategic financings, organizational development, and long-term value creation typical of clinical-stage biotechs. The proposal is advisory and does not alter pay arrangements directly, but the Board and Compensation Committee state they will review and consider vote outcomes when setting future pay. The proxy discloses base salaries, target bonuses, equity awards, severance arrangements, and other benefits for the named executives and describes that the Compensation Committee exercised discretion not to pay cash bonuses for 2025 to conserve cash. Support for the proposal signals shareholder acceptance of management’s pay approach and incentive mix; opposition or significant negative votes would likely prompt a review of pay practices and potentially changes to incentive design, severance terms, or disclosure. Given the company’s clinical-stage profile, much of NEO pay is equity-linked and intended to align management with long-term upside, but shareholders should evaluate realized pay (and severance protections) relative to performance and dilution. In assessing the vote, investors should consider the company’s pay-for-performance alignment, the Compensation Committee’s governance (independence, use of consultants), and potential dilution impact from equity grants when weighing support.